androgen deprivation therapy

Real-World Treatment Patterns, Survival Outcomes in Metastatic Castration-Sensitive Prostate Cancer
Videos
Real-World Treatment Patterns, Survival Outcomes in Metastatic Castration-Sensitive Prostate Cancer
02/25/2021
Stephen Freedland, MD, discusses study results exploring real-world evidence on survival outcomes among men with metastatic castration-resistant prostate cancer who initiated ADT or ADT combined with anti-androgens, docetaxel, or abiraterone.
Stephen Freedland, MD, discusses study results exploring real-world evidence on survival outcomes among men with metastatic castration-resistant prostate cancer who initiated ADT or ADT combined with anti-androgens, docetaxel, or abiraterone.
Stephen Freedland, MD, discusses...
02/25/2021
Journal of Clinical Pathways
Apalutamide Plus ADT Improves Long-Term Survival in Metastatic Castration-Sensitive Prostate Cancer
Videos
Apalutamide Plus ADT Improves Long-Term Survival in Metastatic Castration-Sensitive Prostate Cancer
02/14/2021
02/14/2021
Journal of Clinical Pathways
News
Addition of ADT, Brachytherapy to External Beam Radiotherapy for Localized Prostate Cancer
06/03/2020
Androgen deprivation therapy (ADT) should be considered a critical component of treatment for men with intermediate- and high-risk prostate cancer regardless of radiotherapy delivery method, according to new...
Androgen deprivation therapy (ADT) should be considered a critical component of treatment for men with intermediate- and high-risk prostate cancer regardless of radiotherapy delivery method, according to new...
...
06/03/2020
Journal of Clinical Pathways
Research in Review
ADT Not Associated With Increased Risk of Dementia for Patients With Prostate Cancer
02/01/2017
JCP Editors
Treating advanced prostate cancer with androgen deprivation therapy (ADT) does not increase risk of Alzheimer’s disease, according to research published in the Journal of Clinical Oncology. ADT is prescribed to men...
Treating advanced prostate cancer with androgen deprivation therapy (ADT) does not increase risk of Alzheimer’s disease, according to research published in the Journal of Clinical Oncology. ADT is prescribed to men...
...
02/01/2017
Journal of Clinical Pathways
Research in Review
Identifying Risk of All-Cause Mortality In Men Being Treated for Prostate Cancer
01/17/2017
JCP Editors
Men being treated for prostate cancer who are at higher risk of dying as a result of treatment failure can be identified prior to PSA recurrence using a surrogate endpoint, according to a study published in JAMA...
Men being treated for prostate cancer who are at higher risk of dying as a result of treatment failure can be identified prior to PSA recurrence using a surrogate endpoint, according to a study published in JAMA...
Men...
01/17/2017
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use